Pfizer's new vaccine R&D leader Anderson has a high bar to reach in replacing Jansen From Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotech Five dead after shooting at Tulsa's Saint Francis Hospital: 'This campus is sacred ground for our community' Ear 3D-printed from a patient's own cells implanted successfully in first-in-human trial UPDATE: Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks. Why not just buy it? Regeneron pays Sanofi $900M for full rights to cancer drug Libtayo as it looks to become a force in oncology Samantha Truex did a rare thing last time she was CEO: admit defeat. She's back with a new biotech and $200M Oracle secures regulatory approvals for $28B Cerner takeover. Deal set to close next week Diabeloop rounds up €70M to take AI-powered insulin delivery tech global Merck KGaA nabs another baton in protein degradation race with $554M Proxygen deal Moderna, EU officials delay COVID-19 vaccine deliveries as demand falls Expert: Spread of monkeypox underscores need for physicians to be ready to understand disease Featured Story | By Kevin Dunleavy As Pfizer's new chief of vaccine research and development, Annaliesa Anderson has a high bar to reach as she replaces retiring Kathrin Jansen, who climaxed her career with a brilliant swan song—leading Pfizer’s collaboration with BioNTech which produced the world’s most successful COVID-19 vaccine. read more |
| |
|---|
|
| | Biotech got the world back on track. Now, we’re getting back together, and what happens next is Limitless. #BIO2022 |
Top Stories By Gabrielle Masson Michael Severino, M.D., is leaving AbbVie and big pharma behind—but that’s not the end of the story. The leader is already entering his next chapter at Tessera Therapeutics, stepping into the world of biotech as CEO of the gene writing and rewriting company. read more By Dave Muoio Wednesday afternoon's "deliberate" attack sent the 1,112-bed hospital's entire campus into lockdown and led to the deaths of four victims. It is the latest in a string of mass shootings across the country. read more By Andrea Park In news that’ll certainly be music to many ears, a surgeon-led team in Texas was able to successfully implant what it says is the first ear to be 3D-printed using the patient’s own cells. read more By Annalee Armstrong It’s the rare triple down: Bristol Myers Squibb is once again revising a massive research collaboration with immunotherapy drug discovery biotech Immatics. BMS is adding a new deal with $60 million upfront and $700 million down the line for at least two new programs, plus expanding its prior arrangement. read more By Kevin Dunleavy Regeneron has acquired worldwide rights to cancer drug Libtayo from Sanofi for $900 million. Sanofi also will receive an 11% royalty on global sales of Libtayo as well as $100 million in regulatory milestone payments and up to $100 million in sales-related milestone payments over the next two years. read more By Annalee Armstrong The last time Samantha Truex was CEO of a biotech, she did something rare: She admitted defeat. Now, Truex is back at the helm of Upstream Bio, a new inflammatory disease biotech that has been quietly building over the past few months and is ready to reveal today with a whopping $200 million in financing. read more By Heather Landi Software maker Oracle cleared the final regulatory hurdle for its pending $28.3 billion acquisition of Cerner, the companies announced Wednesday. The deal is set to close next week. read more By Andrea Park Diabeloop's hybrid closed-loop insulin delivery system may soon make its way stateside, thanks to an infusion of venture capital that the French company announced this week. read more By Max Bayer As the protein degradation field continues to grow, Merck KGaA has decided it needs more than one baton in the metaphorical clinical relay race, inking a $554 million deal with Austrian biotech Proxygen. read more By Zoey Becker Amid waning COVID-19 vaccine demand in Europe, Moderna and the European Commission agreed to delay some deliveries. read more By Robert King One expert says physicians should be ready to help identify potential cases of monkeypox and know what to look for as spread of the virus continues across the globe. read more | 